Table 2:

Association between Statin Use and Change in Cognition over Time

	CN			EMCI
	Parameter Estimate (SE)	F (dfN, dfD)	p-value	Parameter Estimate (SE)	F (dfN, dfD)	p-value
Memory	0.000 (0.002)	0.001 (1, 1155)	0.980	0.006 (0.003)	5.55 (1, 799)	0.019*
EF	−0.002 (0.003)	0.67 (1, 1150)	0.415	−0.004 (0.004)	1.44 (1, 795)	0.231
ADAS-11	0.004 (0.017)	0.05 (1, 1161)	0.818	−0.033 (0.027)	1.51 (1, 791)	0.220
	LMCI			AD-dementia
	Parameter Estimate (SE)	F (dfN, dfD)	p-value	Parameter Estimate (SE)	F (dfN, dfD)	p-value
Memory	−0.002 (0.002)	1.11 (1, 1482)	0.293	−0.004 (0.003)	2.11 (1, 765)	0.147
EF	0.002 (0.002)	0.40 (1, 1467)	0.526	−0.003 (0.003)	0.99 (1, 742)	0.321
ADAS-11	0.035 (0.025)	1.97 (1, 1489)	0.160	0.078 (0.057)	1.86 (1, 778)	0.173

Parameter Estimates, F-values, and p-values are for separate repeated measures linear mixed effects models in which the interactions of statin use and time are the main explanatory variables. Parameter estimates can be interpreted as rate of change over time in either ADAS-score, memory score, or executive function score. Separate models were fit for each diagnostic group with each cognitive outcome (12 models total). The models were adjusted for age, sex, education, APOE ε4 allele number, and comorbid cardiovascular diagnoses, including HTN, DM, HCL, and CAD, and all interactions with time,

^*p < 0.05 prior to (false discovery rate [FDR]) correction for multiple comparisons.

CN = cognitively normal, EMCI = early Mild Cognitive Impairment, LMCI = late Mild Cognitive Impairment, AD-dementia = dementia due to Alzheimer’s disease, EF = Executive Function, ADAS-11 = Alzheimer’s Disease Assessment Scale-Cognitive Subscale, SE = standard error, df_N = numerator degrees of freedom, df_D = denominator degrees of freedom